Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach.
In the U.S. there are only 4 regular screening protocols for cancer, which detect only 29% of all cancers. Serum contains a myriad of autoantibodies with unique information defining an individual’s immuno-signature, which can include a window into early tumor presence.
Download the white paper to learn about:
Offered Free by: Sengenics
See All Resources from: Sengenics
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.